LAVA Therapeutics NV

LAVA Therapeutics NV — Investor Presentation (January 2023)

40 slides from LAVA Therapeutics NV's investor presentation, Jan 9, 2023

  1. Slide 1: Gamma delta T cell engagers for next-generation cancer therapeutics

    Gamma delta T cell engagers for the development of next - generation cancer therapeutics Corporate presentation January 2023

  2. Slide 2: Legal Disclosure: Forward-looking Statements

    Legal Disclosure: Forward - looking Statements 2 This presentation contains statements that constitute forward - looking statements .. Many of the forward - looking statements contained in this presentation can be identified by the use of forward - looking words such as “anticipate,” “believe,” “cou

  3. Slide 3: Pioneering Next-Generation Cancer Therapeutics

    Pioneering Next - Generation Cancer Therapeutics © LAVA Therapeutics 2023 3 • Bispecific antibody platform to engage Vγ9Vδ2 T cells for highly specific tumor cell killing • Leverage the unique quality of Vγ9Vδ2 T cells to selectively kill tumor cells while sparing normal cells • Fully modular approa

  4. Slide 4: Gammabody Pipeline: Potential in Hematological and Solid Tumor Indications

    MM: multiple myeloma CLL: chronic lymphocytic leukemia AML: acute myeloid leukemia PSMA: prostate - specific membrane antigen EGFR: epidermal growth factor receptor mCRPC : metastatic castration - resistant prostate cancer Gammabody ™ Pipeline: Potential in Hematological and Solid Tumor Indications

  5. Slide 5: Team Led by Experienced Leaders in the Biotech and Pharma Field

    Ton Adang, PhD CDO • Vast experience in drug development • Extensive experience in product discovery and project management (e.g., KEYTRUDA) Hans van der Vliet, MD, PhD CSO • Inventor of LAVA’s gamma delta T cell engager platform • Medical oncologist, extensive experience in pre - clinical and clini

  6. Slide 6: LAVA's Proprietary Gammabody Platform

    LAVA’s Proprietary Gammabody ™ Platform Bispecific Gamma Delta T Cell Engagers 6

  7. Slide 7: High expectations for T cell bispecific therapies

    • High expectations for T cell bi - specific therapies driving significant development • 200+ bispecific antibodies in the clinic • Four marketed bispecific T cell engagers and many in the pipeline • blinatumomab ( Blincyto ); CD3 x CD19 bsTCE (2014) • tebentafusp (KIMMTRAK); CD3 x TCR - fusion targ

  8. Slide 8: Bispecific antibodies entering the clinic by year

    Source: The Antibody Society Data as of Jan. 4, 2023 1 0 1 0 3 1 0 0 0 1 6 4 5 5 10 16 17 21 35 45 31 65 59 0 10 20 30 40 50 60 70 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 c atumaxomab (malignant ascites) Approved in the EU in

  9. Slide 9: Bispecific T Cell Engagers: narrow therapeutic window

    • High expectations for targeted T cell therapies in cancer, but often: • Narrow therapeutic window: • Cytokine Release Syndrome • On - target/off - tumor - related toxicities • Activates immunosuppressive T cells • Sporadic efficacy in solid tumors Therapeutic Window therapeutic effect toxic effect

  10. Slide 10: Strategies for Widening the Therapeutic Window

    • Selecting ‘tumor - specific’ targets • Step - dosing / subcutaneous dosing • Decreasing affinity for T cells • Masking/site - specific activation • Recruiting alternative effector cells • Address only narrow target range, and/or • Cumbersome, and/or • Strongly decrease potency © LAVA Therapeutics

  11. Slide 11: Gammabody Platform: Bispecific γδ T Cell Engagers

    Gammabody ™ Platform: Bispecific γδ T Cell Engagers DIFFERENTIAL APPROACH A versatile bispecific antibody platform for developing novel cancer therapeutics MECHANISM OF ACTION LAVA's proprietary bispecific antibodies are designed to: - Target V γ 9V δ 2 T cells to tumor antigens initiating selective

  12. Slide 12: Bispecific γδ T Cell Engagers Harness Innate and Adaptive Immunity

    Bispecific γδ T Cell - Engagers Aim to Harness Innate and Adaptive Immunity Introducing V γ 9V δ 2 T cells • Largest γδ - T cell subset in blood: (~90 - 95% of total γδ - T cells) • Natural ability to recognize and kill tumor cells • Highly cytotoxic • Relatively abundant in tumor - infiltrating lym

  13. Slide 13: Off-the-Shelf Gammabody Platform

    Off - the - Shelf Gammabody ™ Platform: Enhances Innate Tumor Recognition by Directing Vγ9Vδ2 T Cells to the Cancer Cells © LAVA Therapeutics 2023 13 LAVA’s Gammabody ™ directs V γ9 V δ2 T cells to tumors with high affinity to induce direct tumor cell killing and orchestrate an immunological cascade

  14. Slide 14: Cascade of Anti-Cancer Responses

    Cascade of Anti - Cancer Responses – Potential Translation to Favorable Therapeutic Window © LAVA Therapeutics 2023 14 Efficacy • Potent killing of cancer cells (EC 50 s in the low picomolar range) • No co - activation of immune - suppressive Tregs which dampen antitumor efficacy of cytotoxic T cell

  15. Slide 15: Expansion & Cascade Response Without Treg Activation

    Expansion & Cascade Response Without Treg Activation in Preclinical Models © LAVA Therapeutics 2023 15 Gammabody ™ can induce robust gamma delta T cell expansion and can amplify the anti - tumor immune response via downstream activation of other immune cells while avoiding co - activation of immunos

  16. Slide 16: Gammabody Selectively Kills Cancer Cells While Sparing Healthy Cells

    Gammabody ™ Can Selectively Kill Cancer Cells While Sparing Healthy Cells in Hematologic Malignancy and Solid Tumor models © LAVA Therapeutics 2023 16 CD20 Gammabody ™ Mediated Killing PSMA Gammabody ™ Mediated Killing Preferential killing of cancer versus healthy cells demonstrated in vitro and ex

  17. Slide 17: Non-Clinical Safety Data Indicate Good Tolerability

    Non - Clinical Safety Data Indicate Good Tolerability • Non - clinical safety studies using Gammabody ™ molecules designed for cross - reactivity support the benign safety profile of the platform • NHP studies completed with Gammabody ™ molecules targeting CD1d, CD20 and EGFR • CD1d, CD20 targeting

  18. Slide 18: Gammabody Platform: A Novel T cell engager approach

    Gammabody ™ Platform: A Novel T cell engager approach for cancer therapy © LAVA Therapeutics 2023 18 γδ T cell engager platform • Highly potent (kills at picomolar concentrations) • Recruits additional immune effector cells by antigen presentation and cascade response • No activation of regulatory T

  19. Slide 19: Clinical-stage company

    Clinical - stage company

  20. Slide 20: LAVA-051 Targets CD1d for CLL, MM & AML

    LAVA - 051 Targets CD1d to Activate V γ9 V δ2 T Cells and iNKT Cells for the Potential Treatment of CLL, MM & AML

  21. Slide 21: LAVA-051: First-in-Class Gammabody Targeting CD1d

    LAVA - 051: First - in - Class Gammabody ™ Targeting CD1d © LAVA Therapeutics 2023 21 Format • Humanized bispecific single domain antibody ( bsVHH ) of 27kDa ‒ Short plasma half - life, prolonged functional half - life through high - affinity TCR binding Mechanism of Action • Engages V γ 9V δ 2 T ce

  22. Slide 22: LAVA-051: Pre-Clinical Data Support Mechanism of Action

    LAVA - 051: Pre - Clinical Data Support Mechanism of Action and Function © LAVA Therapeutics 2023 22 Expansion of V γ9 V δ2 T and iNKT cells Lysis of patient tumor cells 0 20 40 60 80 100 CLL specific lysis (relative %) 0 20 40 60 80 100 MM 0 20 40 60 80 100 AML negative control LAVA - 051 0 5 10 15

  23. Slide 23: Phase 1/2a in Hematological Malignancies

    LAVA - 051 Phase 1/2a in Hematological Malignancies © LAVA Therapeutics 2023 23 • Primary objectives: investigate safety and tolerability of LAVA - 051 and determine the recommended Phase 2 dose • Secondary objectives: include evaluation of PK, PD, immunogenicity and preliminary antitumor activity •

  24. Slide 24: LAVA-051 Initial Phase Data: Adverse Events

    LAVA - 051 – Initial Phase 1 Data - Adverse Events © LAVA Therapeutics 2023 24 • LAVA - 051 has reached a dose of 200 m g (~400x the starting dose) in MM and CLL patients • Most observed AEs have not been suspected to be related • Frequency and severity of AEs have not correlated with increasing dos

  25. Slide 25: LAVA-051 Initial Phase Data: Pharmacodynamics

    LAVA - 051 – Initial Phase 1 Data - Pharmacodynamics © LAVA Therapeutics 2023 25 ASCO 2022 abstract 2577; ASH 2022 abstract #2014 Data on file: LAVA Therapeutics N.V • Pharmacodynamic parameters reflect changes expected for the LAVA - 051 mechanism of action • Vγ9Vδ2 - T cell activation markers (CD2

  26. Slide 26: LAVA-051 Pharmacokinetics

    LAVA - 051 - Pharmacokinetics © LAVA Therapeutics 2023 26 Pharmacokinetics 1 st dose IV, 2 nd dose SC patient 32 - 001 cohort #5  IV  SC  IV • Linear LAVA - 051 pharmacokinetics • SC bioavailability 74% compared to IV (based on data from Pt 32 - 001) ASH 2022 abstract #2014 Data on file: LAVA The

  27. Slide 27: Patient Characteristics and Time on Treatment

    LAVA - 051 – Initial Phase 1 Data - Patient Characteristics and Time on Treatment © LAVA Therapeutics 2023 27 MM/CLL 6/6 Male/Female 8/4 Median age (range) 69 (59 - 76) Prior therapies, median (range) – MM/CLL 4 (3 - 5) / 5.5 (4 - 13) ASH 2022 abstract #2014 , corrected Data on file: LAVA Therapeuti

  28. Slide 28: Potential Signs of Activity

    LAVA - 051 – Initial Phase 1 Data - Potential Signs of Activity © LAVA Therapeutics 2023 28 CLL • Patient with R/R CLL ( 15 m g) • Temporary enlargement and tenderness of several involved lymph nodes accompanied by grade 2 fever during Cycle 1 ‒ Resembled a tumor - flare reaction, as reported in CLL

  29. Slide 29: LAVA-051: Summary of Initial Phase Data

    LAVA - 051: Summary of Initial Phase 1 Data Presented © LAVA Therapeutics 2023 29 • LAVA - 051 is a next - generation bispecific γδ T cell engager designed for a broad therapeutic window • LAVA - 051 has reached a dose of 200 m g (400x the starting dose) in MM and CLL patients • Most observed Advers

  30. Slide 30: LAVA-1207 Targeting PSMA for mCRPC

    LAVA - 1207 Gammabody ™ that Activates V γ9 V δ2 T Cells by Targeting PSMA for the Treatment of mCRPC

  31. Slide 31: LAVA-1207: PSMA-targeting Gammabody for Prostate Cancer

    LAVA - 1207: PSMA - targeting Gammabody ™ for Prostate Cancer © LAVA Therapeutics 2023 31 Format • Contains a Fc domain for extended plasma half - life; silenced to avoid off - target T cell activation • Small size (compared to regular IgG antibodies) to facilitate tumor penetration Mechanism of Act

  32. Slide 32: LAVA-1207: Preclinical Activity and Selectivity in Patient Samples

    LAVA - 1207: Preclinical Data Support Activity and Selectivity in Patient Samples © LAVA Therapeutics 2023 32 • LAVA - 1207 triggers activation of autologous V γ9 V δ2 T cells in the presence of patient - derived tumor cells • LAVA - 1207 induces selective tumor cell lysis Medium + LAVA-1207 0 5 10

  33. Slide 33: LAVA-1207 Phase 1/2a in mCRPC

    LAVA - 1207 Phase 1/2a in mCRPC © LAVA Therapeutics 2023 33 • Primary objective: investigate safety and tolerability of LAVA - 1207 and determine recommended dose and schedule based on optimal biological dose • Secondary objectives include evaluation of PK, PD, immunogenicity and preliminary antitum

  34. Slide 34: LAVA-1223 – Licensed to Seagen

    LAVA - 1223 – Licensed to Seagen Gammabody ™ for the treatment of EGFR - expressing solid tumors

  35. Slide 35: LAVA-1223: EGFR-Targeting Gammabody

    LAVA - 1223: EGFR - Targeting Gammabody ™ © LAVA Therapeutics 2023 35 Format • Gammabody ™ format containing a silenced Fc domain Mechanism of Action • Induces preferential lysis of EGFR - expressing tumor cells while relatively sparing EGFR - expressing normal cells Status • Exclusive worldwide lic

  36. Slide 36: LAVA-1266: CD123 Targeting Gammabody

    CD123 Targeting Gammabody ™ for the Treatment of Hematologic Malignancies LAVA - 1266

  37. Slide 37: LAVA-1266: CD123-Targeting Gammabody for Hematological Malignancies

    LAVA - 1266: CD123 - Targeting Gammabody ™ In Development for Treating Hematological Malignancies © LAVA Therapeutics 2023 37 Mechanism of Action • Induces preferential lysis of CD123 - expressing tumor cells while relatively sparing CD123 - expressing normal cells • CD123 is overexpressed in a wide

  38. Slide 38: Milestones

    Milestones

  39. Slide 39: Gammabody Pipeline: Potential in Hematological and Solid Tumor Indications

    MM: multiple myeloma CLL: chronic lymphocytic leukemia AML: acute myeloid leukemia PSMA: prostate - specific membrane antigen EGFR: epidermal growth factor receptor mCRPC : metastatic castration - resistant prostate cancer Gammabody ™ Pipeline: Potential in Hematological and Solid Tumor Indications

  40. Slide 40: LAVA Therapeutics

    LAVA® THERAPEUTICS

LAVA Therapeutics — Investor Presentation (January 2023) on 6ix